Hims & Hers launched a compounded peptide program on Nov. 18 and Noom launched its own a day earlier, according to reporting collected by MedicalDaily from CNBC and Fierce Healthcare. The Hims program, Peptides+, offers five compounded treatments the FDA has not approved: sermorelin, glutathione, NAD+, vitamin B12 and L-carnitine.
Compounded means a licensed pharmacy prepares a drug for an individual patient with a valid prescription, under section 503A of federal drug law and state pharmacy board oversight. That is a legal route, not an approval: Hims' own Peptides+ page states the treatments are not FDA-approved and have not been evaluated by the agency for safety, effectiveness or quality.
Why the distribution matters
These products have been circulating through wellness clinics and online sellers labeled "research use only" for years. What changed this week is the shelf they sit on, and Hims alone has about 2.8 million subscribers.
Noom got its supply chain in April by completing the purchase of Tailor Made Compounding, a 503A pharmacy licensed in 46 states whose formulary already included compounded NAD+, sermorelin, topical GHK-Cu and oxytocin. Hims owns a U.S. compounding pharmacy and a manufacturing facility it acquired in 2025, and says it will later add BPC-157 and TB-500, Reuters reported.
The policy the launches are built on
In April the FDA said it would remove 12 peptides from Category 2, its list of substances raising significant safety concerns, though law firm Orrick noted removal alone did not clear them for compounding. On Oct. 28, HHS Secretary Robert F. Kennedy Jr. announced an interim policy of not acting against compounders making six peptides, including BPC-157 and TB-500, if they meet quality, prescription and reporting conditions.
That is enforcement discretion, not a change in law, according to an analysis by Science-Based Medicine. None of the five products Hims launched are among the six anyway.
Where the evidence stops
Scott Gavura, a pharmacist writing for Science-Based Medicine, argued HHS's evidence for some peptides is asserted but not made public, and that "without meaningful surveillance, the absence of observed harms should not be reassuring." Critics cited by Reuters have warned of contamination, impurities and unknown side effects.
Kennedy and other supporters argue a regulated domestic route beats overseas sellers. Better manufacturing lowers the odds of a contaminated vial, but it says nothing about whether a product works.
Bottom line
None of the five Hims products has FDA approval for the anti-aging, recovery or wellness uses being marketed, and insurance generally does not cover them. Hims' own CFO expects peptide revenue to be "immaterial through the year," which makes the distribution shift, not the sales, the story here.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.